Wyeth Provides Phase-III Updates For Pneumococcal Drug

New Jersey-based Wyeth has announced that the new data from phase-III clinical trials shows that investigational pneumococcal vaccine, Prevenar13, has the potential to provide coverage against the 13 most prevalent serotypes associated with pneumococcal disease (PD).

The phase-III data was presented at the 27th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID).

The clinical trial were conducted at different site across France, Italy, and Poland. Data from the studies demonstrated that Prevenar 13 is immunogenic for all serotypes, and showed a safety profile similar to Prevenar.

Emilio Emini, Executive Vice President of Vaccines Research and Development at Wyeth, said: “Our investigational vaccine, Prevenar 13, builds on the scientific foundation of Prevenar and is designed to provide more comprehensive protection against pneumococcal disease.”

“These new data indicate that Prevenar 13 has the potential to provide direct coverage of the 13 most common disease-causing serotypes, including 3, 6A and 19A, which have been increasing in prevalence in many regions around the world,” he added.